[go: up one dir, main page]

IL127566A0 - Substituted 6,5-hetero- bicyclic derivatives - Google Patents

Substituted 6,5-hetero- bicyclic derivatives

Info

Publication number
IL127566A0
IL127566A0 IL12756697A IL12756697A IL127566A0 IL 127566 A0 IL127566 A0 IL 127566A0 IL 12756697 A IL12756697 A IL 12756697A IL 12756697 A IL12756697 A IL 12756697A IL 127566 A0 IL127566 A0 IL 127566A0
Authority
IL
Israel
Prior art keywords
hetero
substituted
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
IL12756697A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21823717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127566(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL127566A0 publication Critical patent/IL127566A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
IL12756697A 1996-08-28 1997-07-25 Substituted 6,5-hetero- bicyclic derivatives IL127566A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2503996P 1996-08-28 1996-08-28
PCT/IB1997/000922 WO1998008847A1 (fr) 1996-08-28 1997-07-25 Derives 6,5-hetero-bicycliques substitues

Publications (1)

Publication Number Publication Date
IL127566A0 true IL127566A0 (en) 1999-10-28

Family

ID=21823717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12756697A IL127566A0 (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero- bicyclic derivatives

Country Status (36)

Country Link
EP (1) EP0923582B1 (fr)
JP (2) JP3621706B2 (fr)
KR (1) KR20000035934A (fr)
CN (1) CN1227554A (fr)
AP (1) AP762A (fr)
AR (1) AR015103A1 (fr)
AT (1) ATE340176T1 (fr)
AU (1) AU735401B2 (fr)
BG (1) BG103189A (fr)
BR (1) BR9711970A (fr)
CA (1) CA2263566C (fr)
CO (1) CO4600634A1 (fr)
CZ (1) CZ68199A3 (fr)
DE (1) DE69736711T2 (fr)
DZ (1) DZ2300A1 (fr)
EA (1) EA002769B1 (fr)
ES (1) ES2273369T3 (fr)
GT (1) GT199700095A (fr)
HR (1) HRP970454B1 (fr)
HU (1) HUP9903965A3 (fr)
ID (1) ID18249A (fr)
IL (1) IL127566A0 (fr)
IS (1) IS4963A (fr)
MA (1) MA26438A1 (fr)
NO (1) NO313636B1 (fr)
NZ (1) NZ333302A (fr)
OA (1) OA10977A (fr)
PA (1) PA8436201A1 (fr)
PE (1) PE108898A1 (fr)
PL (1) PL332040A1 (fr)
SK (1) SK23399A3 (fr)
TN (1) TNSN97145A1 (fr)
TR (1) TR199900389T2 (fr)
TW (1) TW575573B (fr)
WO (1) WO1998008847A1 (fr)
ZA (1) ZA977687B (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716993B2 (en) 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
WO1998035967A2 (fr) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et procedes associes
WO1998047903A1 (fr) * 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Thiophenopyridines antagonistes du crf
IL133800A0 (en) * 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999051597A1 (fr) 1998-04-02 1999-10-14 Neurogen Corporation Derives de 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole et de 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole a substitution aminoalkyl: des ligands specifiques du crf1
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
WO1999051608A1 (fr) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company PYRIMIDINES ET PYRIDINES THIAZOLO[4,5-d] UTILISEES COMME ANTAGONISTES DU FACTEUR LIBERATEUR DE CORTICOTROPHINE (CRF)
DE69907448T2 (de) * 1998-06-09 2004-03-18 Neurogen Corp., Branford Pyrido[2,3-b]indolizinderivate und aza analoge: crf1 spezifische liganden
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
WO2000011003A1 (fr) * 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company Isoxazolo[4,5-d]pyrimidines comme antagonistes du crf
BR9915129A (pt) 1998-11-12 2001-08-07 Neurocrine Biosciences Inc Antagonistas do receptor de crf e processos relacionados aos mesmos
HK1038926B (en) * 1998-11-12 2003-07-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
CA2359041A1 (fr) * 1999-01-29 2000-08-03 Sumitomo Chemical Co., Ltd. Agents inhibiteurs d'accumulation de graisse
EP1040831A3 (fr) * 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2000059907A2 (fr) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines antagonistes de corticoliberine (crf)
EP1669071B1 (fr) * 1999-05-21 2009-07-22 Bristol-Myers Squibb Company Pyrrolotriazines comme inhibiteurs des kinases.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
EP1293213A1 (fr) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Agents prophylactiques/therapeutiques contre le stress postoperatoire
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
EP1149583A3 (fr) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance
AU2001263288A1 (en) * 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1354884B1 (fr) 2000-12-28 2007-10-10 Ono Pharmaceutical Co., Ltd. Compose cyclopenta[d]pyrazolo[1,5-a]pyrimidine comme antagoniste du recepteur du crf
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DE60218434T2 (de) * 2001-03-13 2007-11-08 Bristol-Myers Squibb Pharma Co. 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
US7446108B2 (en) 2001-05-21 2008-11-04 Neurocrine, Inc. Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
EP1485385B1 (fr) 2002-03-07 2005-08-17 SmithKline Beecham Corporation Pyrazolopyrimidine, derives de pyrazolotriazine et compositions pharmaceutiques contenant lesdits derives
EP1348707B1 (fr) * 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, procédé pour leur préparation et application thérapeutique
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
DE60326869D1 (de) 2002-10-22 2009-05-07 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
WO2004076450A1 (fr) * 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Derives de pyrazolopyridine
US7041671B2 (en) * 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) * 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2006523675A (ja) * 2003-04-15 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロロ［１，２−ｂ］ピリダジン化合物及びそれらの使用
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
MXPA05011993A (es) * 2003-05-07 2006-02-02 Pharmacia & Upjohn Co Llc Compuestos de pirrolo[1,2-b]piridazina.
WO2004110454A1 (fr) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2287165A3 (fr) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
CN1878773A (zh) * 2003-09-05 2006-12-13 神经能质公司 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en) 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
RU2394035C2 (ru) 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
RU2367663C2 (ru) * 2004-01-06 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные пирролопиримидина и пирролотриазина
CA2552598A1 (fr) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de thienopyrimidine et de thienopyridine substitues par un groupe amino cyclique
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
ATE430746T1 (de) * 2004-10-19 2009-05-15 Smithkline Beecham Cork Ltd Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
EP2537520A1 (fr) 2005-03-29 2012-12-26 Biocryst Pharmaceuticals, Inc. Thérapies hépatiques C
US20090234117A1 (en) * 2005-05-27 2009-09-17 Toshihiko Kashiwagi Pyrazolopyrimidine Derivative
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CA2615946A1 (fr) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolopyrimidines utiles comme inhibiteurs de la kinase aurora
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
ES2428543T3 (es) 2006-09-20 2013-11-08 Eli Lilly And Company Compuestos de tiofenopirazolopirimidina
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
KR20100108390A (ko) 2007-12-19 2010-10-06 버텍스 파마슈티칼스 인코포레이티드 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (fr) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés de triazolopyridine utiles en tant qu'inhibiteurs de dgat1
BRPI0911659B8 (pt) 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CA2790176A1 (fr) * 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Composes bicycliques destines a etre utilises en tant qu'inhibiteurs de kinases
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US8450320B2 (en) * 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
EP2563792B1 (fr) 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Composés d'imidazopyridazinyle et leurs utilisations pour le cancer
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103328473A (zh) 2010-11-12 2013-09-25 百时美施贵宝公司 取代的氮杂吲唑化合物
EP2651948A1 (fr) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
CA2821837A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines 2-substituees pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation
ES2556458T3 (es) 2010-12-17 2016-01-18 Bayer Intellectual Property Gmbh 6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
WO2012149157A2 (fr) * 2011-04-26 2012-11-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
WO2013135612A1 (fr) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Imidazopyridazines substituées
KR102171706B1 (ko) * 2012-07-09 2020-10-30 얀센 파마슈티카 엔.브이. 포스포디에스테라아제 10 효소의 억제제
HRP20161125T1 (hr) 2012-07-13 2016-11-18 Janssen Sciences Ireland Uc Makrociklički purini za liječenje virusnih infekcija
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
WO2014066743A1 (fr) 2012-10-25 2014-05-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
WO2014066795A1 (fr) 2012-10-25 2014-05-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
EP2970307B1 (fr) 2013-03-13 2020-03-11 Genentech, Inc. Composés pyrazolo et leurs utilisations
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
KR102280559B1 (ko) 2013-05-24 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체
LT3008062T (lt) 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
NO3030563T3 (fr) 2013-06-27 2018-01-06
AU2014298540B2 (en) 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP2940022B1 (fr) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines comme inhibiteurs de protèines kinases
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
RU2699568C2 (ru) * 2015-12-21 2019-09-06 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Лиганды транслокаторного белка TSPO, обладающие антидепрессивной и ноотропной активностью
EP3478688A1 (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines pour le traitement d'infections virales
EP3519406B1 (fr) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Prodrugs des composés de pyrimidine pour le traitement des infections virales et autres maladies
WO2019036503A1 (fr) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Antagonistes du récepteur du facteur de libération de la corticotropine
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
EP4175572A4 (fr) 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Procédés et compositions pour traiter le syndrome des ovaires polykystiques
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
AU716993B2 (en) * 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands

Also Published As

Publication number Publication date
JP2000502723A (ja) 2000-03-07
DE69736711T2 (de) 2007-09-20
AR015103A1 (es) 2001-04-18
GT199700095A (es) 1999-02-16
CO4600634A1 (es) 1998-05-08
AU3456197A (en) 1998-03-19
TW575573B (en) 2004-02-11
TR199900389T2 (xx) 2000-06-21
DZ2300A1 (fr) 2002-12-25
IS4963A (is) 1999-01-29
JP2005047930A (ja) 2005-02-24
PE108898A1 (es) 1999-01-26
NZ333302A (en) 2000-08-25
HUP9903965A3 (en) 2002-02-28
EA002769B1 (ru) 2002-08-29
SK23399A3 (en) 2000-08-14
NO990927L (no) 1999-02-26
ID18249A (id) 1998-03-19
CN1227554A (zh) 1999-09-01
TNSN97145A1 (fr) 2005-03-15
ZA977687B (en) 1999-03-01
EP0923582B1 (fr) 2006-09-20
BG103189A (en) 1999-09-30
ES2273369T3 (es) 2007-05-01
MA26438A1 (fr) 2004-12-20
WO1998008847A1 (fr) 1998-03-05
KR20000035934A (ko) 2000-06-26
HRP970454B1 (en) 2002-10-31
CZ68199A3 (cs) 1999-11-17
NO990927D0 (no) 1999-02-26
PL332040A1 (en) 1999-08-16
AU735401B2 (en) 2001-07-05
OA10977A (en) 2001-11-02
DE69736711D1 (de) 2006-11-02
NO313636B1 (no) 2002-11-04
AP762A (en) 1999-09-13
CA2263566C (fr) 2003-09-09
AP9701077A0 (en) 1997-10-31
ATE340176T1 (de) 2006-10-15
EA199900165A1 (ru) 1999-08-26
EP0923582A1 (fr) 1999-06-23
PA8436201A1 (es) 1999-12-27
CA2263566A1 (fr) 1998-03-05
HRP970454A2 (en) 1998-08-31
BR9711970A (pt) 1999-08-24
HUP9903965A2 (hu) 2000-03-28
JP3621706B2 (ja) 2005-02-16

Similar Documents

Publication Publication Date Title
IL127566A0 (en) Substituted 6,5-hetero- bicyclic derivatives
ZA977652B (en) Substituted 6,6-hetero-bicyclic derivatives
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
ZA976954B (en) Substituted pyrido- or pyrimido- containing 6,6- or 6,7-bicyclic derivatives
IL141908A0 (en) 1,4-benzodiazepine derivatives
ZA97521B (en) 19-Nor-pregnene derivatives.
PL329121A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
HU9802807D0 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
IL126702A0 (en) 2,4-Diaminopyrimidine derivatives
GB2311779B (en) 2,3 benzodiazepine derivatives
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
CY2322B1 (en) Benzoaeguequinoline derivatives.
ZA971167B (en) Heterocyclyl-ergoline derivatives.
SG70589A1 (en) 1, 25-Dihydroxy-16, 22, 23-trisdehydro-cholecalciferol derivatives
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
IL129029A0 (en) 8(9)-Dehydroestradiol derivatives
SI0920429T1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
ZA965384B (en) 4-Amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
ZA972692B (en) Pyrrolopyrrolone derivatives.
ZA977881B (en) N-benzylazolium derivatives.